Early observations and pilot data that first suggested a new direction
Traditional varicose vein surgery involved high ligation and stripping of the great saphenous vein (GSV) under general anesthesia, with phlebectomies for branch varicosities. While effective, the procedure required hospital admission, carried risks of wound complications, saphenous nerve injury, and significant bruising, and had recurrence rates of 20-30% at 5 years. Patient dissatisfaction with the invasiveness and recovery time of stripping surgery drove demand for minimally invasive alternatives. The development of endovenous laser ablation (EVLA) by Navarro in 2001 and radiofrequency ablation (RFA, ClosureFAST) offered the possibility of treating saphenous reflux through a percutaneous approach under local anesthesia in an office setting, fundamentally changing the treatment paradigm.
Landmark RCTs and pivotal trials that established the evidence base
Multiple RCTs established the equivalence or superiority of endovenous ablation over stripping. The pivotal CLASS trial (randomizing 798 patients to EVLA, foam sclerotherapy, or surgery) demonstrated that EVLA was superior to surgery at 5 years for both technical success and quality of life outcomes, with faster recovery and less pain. The LARA trial confirmed RFA was non-inferior to stripping with significantly less postoperative pain. A Cochrane review incorporating multiple trials concluded that endovenous thermal ablation (EVLA and RFA) had equivalent or superior efficacy to surgery with fewer complications and faster return to normal activities. These results, combined with the ability to perform procedures under local anesthesia in office settings, made endovenous ablation the new standard of care for saphenous vein incompetence.
Follow-up studies, subgroup analyses, and real-world validation
Two important extensions broadened the varicose vein treatment landscape. First, non-thermal non-tumescent (NTNT) techniques emerged, including cyanoacrylate glue closure (VenaSeal) and mechanochemical ablation (ClariVein), which eliminated the need for tumescent anesthesia entirely. The VeClose trial showed cyanoacrylate closure was non-inferior to RFA at 5 years. Second, the EVRA trial (450 patients) provided practice-changing evidence for venous leg ulcers, demonstrating that early endovenous ablation of superficial reflux (within 2 weeks) significantly improved ulcer healing compared to deferred intervention after compression therapy. This was a landmark shift—venous ulcers had traditionally been managed with prolonged compression before considering intervention, and EVRA showed that early ablation healed ulcers faster and more completely.
Integration into clinical practice guidelines and recommendations
NICE guidelines (updated 2020) recommend endothermal ablation (EVLA or RFA) as first-line treatment for saphenous vein incompetence, with ultrasound-guided foam sclerotherapy as second-line if thermal ablation is unsuitable, and surgery as third-line. The SVS/AVF clinical practice guidelines similarly recommend endovenous ablation over surgery. For venous leg ulcers, NICE now recommends early referral for assessment of superficial reflux and endovenous ablation within 2 weeks based on the EVRA evidence. The European Society for Vascular Surgery (ESVS) guidelines provide a comprehensive treatment algorithm incorporating thermal ablation, NTNT techniques, foam sclerotherapy, and surgery based on vein anatomy and patient preference.
NICE Guidelines on Varicose Veins (CG168, updated 2020)
Endothermal ablation (EVLA/RFA) first-line; foam sclerotherapy second-line; surgery third-line. For venous ulcers, early endovenous ablation within 2 weeks
ESVS Clinical Practice Guidelines on the Management of Chronic Venous Disease
Endovenous thermal ablation recommended as first-line for GSV and SSV incompetence; NTNT techniques acceptable alternatives; early intervention for venous ulcers
Now
Current standard of care and ongoing research directions
Varicose vein treatment has moved almost entirely to the office-based outpatient setting. Endovenous thermal ablation (EVLA and RFA) remains the gold standard, with NTNT techniques (cyanoacrylate glue, mechanochemical ablation) offering even less invasive options for patients who prefer to avoid tumescent anesthesia. Foam sclerotherapy remains valuable for branch varicosities and recurrent veins. The most impactful recent change is the evidence from EVRA driving early intervention for venous ulcers rather than prolonged conservative management. Long-term data continue to accumulate for newer NTNT technologies, with the main concern being cost relative to established thermal methods. Ongoing research includes comparative effectiveness of glue versus thermal ablation in larger populations, treatment of perforator incompetence, and optimal management of recurrent varicose veins after initial ablation.
Which endovenous technique has the best long-term outcomes?+
EVLA and RFA have the most robust long-term data, with 5-year anatomic closure rates of 90-95%. The CLASS trial showed EVLA was superior to both foam sclerotherapy and surgery at 5 years. RFA (ClosureFAST) has similar efficacy with potentially less postprocedural pain. Cyanoacrylate glue (VenaSeal) showed non-inferiority to RFA at 5 years in the VeClose trial but has less long-term data. All endovenous techniques are superior to foam sclerotherapy alone for truncal saphenous incompetence.
Should venous ulcers be treated with compression alone before considering ablation?+
No. The EVRA trial demonstrated that early endovenous ablation of superficial reflux within 2 weeks—combined with compression—healed venous ulcers significantly faster than deferred ablation after compression alone (median healing 56 vs 82 days). Patients with venous ulcers and superficial reflux on duplex should be referred urgently for endovenous intervention rather than managed with prolonged compression therapy first.
What is the role of foam sclerotherapy in modern varicose vein treatment?+
Foam sclerotherapy (ultrasound-guided injection of polidocanol or sodium tetradecyl sulfate foam) is recommended as second-line treatment when endovenous thermal ablation is unsuitable—for example, very tortuous veins, small-caliber veins, or recurrent varicosities. It is also widely used for branch varicosities after truncal ablation. The CLASS trial showed foam had higher recurrence rates than EVLA at 5 years. Foam is the most cost-effective treatment and is valuable in resource-limited settings, but thermal ablation provides superior durability.
What are the advantages of non-thermal non-tumescent (NTNT) techniques?+
NTNT techniques (cyanoacrylate glue closure, mechanochemical ablation) eliminate the need for tumescent anesthesia—multiple injections of dilute lidocaine along the vein—which is the most uncomfortable part of thermal ablation. This reduces procedural pain, eliminates the (very rare) risk of tumescent-related nerve injury, and simplifies the procedure. Disadvantages include higher device costs, less long-term data, and the potential for allergic reactions with cyanoacrylate glue. NTNT techniques are particularly useful for veins near nerves (small saphenous vein) where tumescent-related nerve injury is a concern.
